Drug Trial Radar · NCT06111014
Continuation Study for Latozinemab
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
17
Actual
Start
Dec 8, 2023
Primary completion
Sep 1, 2025
Study completion Jan 7, 2026
Sponsor
- Lead sponsor
- Alector Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
Conditions
- Neurodegenerative Diseases
Interventions
LatozinemabDrug
All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants receiving latozinemabTime frame: Through study completion, up to 190 weeks
- Duration of treatment with latozinemabTime frame: Through study completion, up to 190 weeks
Locations
18 sites in 10 countries. Site status is shown where the registry gives one.
Dignity Health - Arizona
Phoenix, Arizona
Mayo Comprehensive Cancer Center - PPDS
Rochester, Minnesota
Irving Institute for Clinical and Translational Research
New York, New York
University of Cincinnati Gardner Neuroscience Institute
Cincinnati, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
UZ Leuven
Leuven, Belgium
Parkwood Institute
London, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Groupe Hospitalier Pitié Salpétrière
Paris, France
Universitätsklinikum Ulm - Leimgrubenweg 12-14
Ulm, Germany
IRCCS - Centro S. Giovanni di Dio Fatebenefratelli
Brescia, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico -Via Fracesco Sforza 35
Milan, Italy
Azienda Ospedaliero Universitaria Di Modena Policlinico
Modena, Italy
Erasmus MC-Dr. Molewaterplein 40
Rotterdam, Netherlands
Centro Hospitalar E Universitario de Coimbra EPE
Coimbra, Portugal
Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria
Lisbon, Portugal
Karolinska Universitetssjukhuset Huddinge
Huddinge, Sweden
University College London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.